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To investigate whether immune pressure enhances the genetic diversity of the hepatitis C virus (HCV) hypervariable region
1, nucleotide sequences were compared in multiple sera, collected longitudinally, from three untreated patients and four
patients undergoing liver transplantation for HCV-related cirrhosis. A minor variant became dominant in three of three patients
following transplantation and persisted unchanged for months. Compared with untreated HCV carriers, transplant recipients
had fewer quasispecies, fewer nucleotide changes (1.61 and 2.58/month), fewer amino acid sequence changes (0.40 and
1.94/month), as well as higher ratio of transitional to transversional mutations (2.57 and 0.98, P  0.02) and lower replacement
to silent mutations (1.33 and 8.21, P  0.01). The two patients with the least genomic variation died of HCV graft infection.
The data suggest that HCV variants which infect the graft are selected by recipient immune pressure at the time of transplant
and that preferential replication in the graft is enhanced by routine immunosuppression. q 1997 Academic Press
Some individuals with chronic hepatitis C virus (HCV) immunosuppressive treatment with cyclosporine, predni-
solone, and azathioprine. Patients 5–7 were apparentlyinfection develop cirrhosis and many will require liver
transplantation (1, 2). Almost invariably, the liver allograft healthy blood donors with a past history of intravenous
drug abuse.serves as target for HCV infection (3, 4). HCV is remark-
able for its high degree of genomic variability in two RNA extraction was performed according to standard
methods. Oligonucleotide primers for amplification of thediscrete areas of the E2 structural region termed hyper-
variable region 1 and 2 (HVR1 and 2). Sequences from HVR1 region and the 3* end of the E1 region were used
(9, 10): outer primers 3768 (5* GGI CAY CGY ATG GCImultiple cDNA clones of individual patient sera revealed
a variable degree of genomic diversity within HVR1 and TGG GA [sense]) and 3769 (3* CIR TCG GTI GTI CCC
ACB AC [antisense]) and the corresponding inner prim-reflected in a population of viral mutants called quasispe-
cies (5–7). To explore the role of immune pressure in ers 3766 (5* GGG AYA TGA TGA TRA ACT GG [sense])
the genomic variability of HCV, we compared the se- and 3770 (3* CAG TAI ACY GGR CCR CAY AC [anti-
quences of HVR1 in a group of patients who underwent sense]). Type-specific sequence homologies contained
liver transplantation for HCV-related end-stage cirrhosis within the amplified region enabled a simultaneous de-
and a reference group of patients with HCV-related termination of the HCV type (10). Reverse transcription
chronic liver disease who did not receive any treatment. and first PCR were combined as described (11). The
Seven patients with HCV infection were included in amplified PCR product was sequenced by the dideoxy
the study (Table 1). All had antibody to HCV detected by nucleotide chain termination method (USB sequencing
screening with an enzyme-linked immunosorbent assay kit). Ten to 14 cDNA clones per patient sample were
(Abbott Laboratories, Chicago, IL) and confirmed with sequenced. The nucleotide sequence diversity in each
RIBA2 (Ortho Diagnostics, Raritan, NJ). All were positive set of sequences was calculated as the percentage of
for HCV RNA detected by nested polymerase chain reac- nucleotide differences from the dominant sequence of
tion (PCR) using previously described primer pairs in the the initial sample. Replacement over silent (R/S) mutation
highly conserved 5* noncoding region (8). Patients 1– 4 ratios were calculated. In addition, amino acid se-
underwent one or two liver transplants during the course quences were deduced and conservative and noncon-
of the study subsequent to which they received standard servative mutations were determined and analyzed.
Primers and probes for the quantitative nested PCR
were selected in the core region. Outer primers were
Sequence data from this article have been deposited with the EMBL
sense 5*-GCGCGAIAGGAAGACTTCG-3* (481–499), anti-Data Library under Accession Nos. Z83699–Z83730.
sense 5*-GATGTACCCCATGAGGTCGG-3* (732–751);1 To whom correspondence and reprint requests should be ad-
dressed. Fax: 44.1223.242.044. inner primers were sense 5*-CGTGGAAGGCGACAA-
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FIG. 1. (A) Nucleotide (nt) and (B) deduced amino acid sequences of the HCV HVR1 region of patient 1. Both sequences are aligned with the
most frequently found variant (dominant quasispecies) in the first time point sample. Dots indicate identity with the nucleotide or amino acid lead
sequence. Lowercase indicates silent and capital replacement mutations. Letter ‘‘T’’ followed by a number corresponds to time from transplantation
in days. The number of clones (right-hand column) corresponds to the number of identical sequences found in each sample. ‘‘No. of sequences’’
indicates the number of identical deduced amino acid sequences in each sample. Nucleotide 1 corresponds to nt 1489 of HC-J8 (9).
CCTAT-3* (515–535), anti-sense 5*-CGCATGTTAGGG- were still detectable after 1 year of follow-up in patient
1 (Fig. 1). The HVR1 regions of patients 1 and 3 wereTATCGAT-3* (706–725); probe was 5*-ATGGGCTGG-
GCAGGATGGCTC-3* (611 –632), 5* digoxigenin labeled. sequenced in five serial serum samples over approxi-
mately 1 year (Figs. 1 and 2). In both cases, only silentQuantitation was done by scanning bands after hybrid-
ization from a standard containing a known number of mutations were observed in the dominant variant, and
the deduced amino acid sequences remained constant.copies to draw a curve against which each sample was
quantitated (12). When applicable, comparison of ratios This relative lack of mutation contrasted markedly with
results from patients 5 and 6 who had not received immu-was done using the Fisher exact test. A P value  0.05
was considered significant. nosuppressive treatment and were followed-up over a
similar time interval. In both cases, mutations corre-As shown in Table 1, the levels of viremia pretrans-
plantation and in untreated patients were similar. In con- sponded to the occurrence of nine deduced amino acid
replacements of the 27 total amino acids of the HVR1trast, approximately 3 months posttransplantation, levels
of viremia increased 10 to over 100 times and tended to region (Table 1).
The HVR1 nucleotide and amino acid sequence diver-subsequently decline.
The HVR1 sequences of patients 1, 2, and 4 were sity in four immunosuppressed and three untreated pa-
tients was compared. As shown in Table 1, the averagedetermined within the month preceding and 2 to 3
months following transplantation (Fig. 1, Table 1). In each number of variants per sample was lower in the immuno-
suppressed patients (range 1–6, mean 3.14) than in thecase, a minor variant or a closely related variant present
prior to transplantation became dominant or exclusive nontreated patients (range 2–10, mean 4.5). This differ-
ence was even more marked when samples precedingfollowing the procedure (Figs 1 and 2). In patient 1 only
one of the five observed mutations led to a conservative immunosuppression were discounted (mean 3.0). Taking
as reference the dominant variant sequence of each ini-amino acid replacement. In patients 1 and 4, mutations
of pretransplant minor variants produced deduced amino tial sample, the mean percentage of nucleotide variation
was 3.5% for the 10 follow-up samples of immunosup-acid replacements that persisted posttransplantation and
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FIG. 2. (A) Nucleotide and (B) deduced amino acid sequences of the HCV HVR1 region of patient 3. See legend to Fig. 1.
pressed patients and 13.5% for the 5 samples from the plantation, 14 and 13 months after the first transplanta-
tion, respectively. In contrast, patients 2 and 4 had un-untreated patients. When the periods of observation were
summed up for each group of patients, untreated patients complicated transplantation outcome after 20 months
and 1 year of follow-up, respectively.and liver transplant recipients had averages of 2.58 and
1.61 nucleotide substitutions per month, respectively. The main feature of the comparison of pre- and post-
transplantation distribution of quasispecies is the appar-The ratio between transition and transversion of nucleo-
tides was significantly different: 0.98 and 2.57 (P  0.02) ent selection of a minor quasispecies to infect the trans-
planted liver (Fig. 1). This phenomenon can be explainedin the untreated and immunosuppressed groups, respec-
tively. The ratio R/S was significantly higher in untreated if the minor quasispecies are more infectious escape
mutants unrecognized by the patient immune system atpatients (8.21 vs 1.33, P  0.01).
A total of 259 HVR1 sequences were obtained, 85 from the time of transplantation (13). In patients 1, 3, 5, and
6, two samples collected at approximately 1-year intervaluntreated patients and 174 from transplanted patients.
The respective positions of these mutations for each pa- were examined. In the two immunosuppressed patients
(Figs. 1 and 2) there were 0 and 3 mutated nucleotidetient in these two groups were plotted. Of the 81 nucleo-
tide positions of the HVR1 sequence, 24 (30%) were con- positions, while in the two patients who followed a natu-
ral history course, 14 and 23 were observed. This wasserved, 12 of them encoding five conserved deduced
amino acids at positions 2, 6, 7, 23, and 26. All other consistent with results of other groups (14). In untreated
patients 5 and 6, 10 and 15 amino acid replacementsareas had a degree of variability. This was relatively high
in two areas (hot spots) for both groups of patients: nucle- were observed, respectively. These numbers were mark-
edly higher than 0 and 3 substitutions observed in pa-otide positions 25–40 and 62–65. In contrast, the region
spanning nucleotide positions 43–55 was largely vari- tients 1 and 3. These results are consistent with previous
reports (6, 15, 16). Most frequent nucleotide substitutionsable in the untreated patients but not in the immunosup-
pressed patients. were limited to two hot spots of the HVR1: nucleotides
25 to 40 and 62 to 65, but were extended to nucleotidesBoth patients 1 and 3 required a second liver trans-
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25–66 in both patient groups. Except for the nucleotides untreated patients with chronic liver disease. They
strongly suggest that temporal changes in viral species25–27 coding for amino acid 9, the mutation rate in un-
distribution is largely driven by immune pressure sincetreated patients and to a lesser extent in immunosup-
the removal of this pressure limits the viral diversity.pressed patients is the highest at positions coding for
the HVR1 epitope I described by Kato et al. (17) (nucleo-
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